Quark Biosciences (QuarkBio), established in 2012, was founded on the belief that traditional "one-size-fits-all" healthcare approaches have been insufficient in addressing the diverse needs of patients. In response to the growing demand for precision medicine and personalized health solutions, QuarkBio has dedicated itself to developing innovative molecular diagnostics. By collaborating with doctors and researchers worldwide, QuarkBio focuses on providing advanced molecular testing solutions for infectious diseases, cancer, fertility treatments, and overall health. These tests are powered by their patented NextAmp™ Analysis System, a chip-based multi-gene analyzer. With this device, up to 300+ gene testing can be completed within 2 hours, with an automatically generated report. This system offers high accuracy, minimal hands-on time, and cost-effectiveness, making it a valuable tool for healthcare professionals. Additionally, QuarkBio has developed AI-based algorithms to analyze test data, enabling the creation of personalized treatment solutions tailored to each patient’s unique needs